Newer Antiarrhythmic Drugs

Michelson, Eric L.; Dreifus, Leonard S.

doi:10.1016/s0025-7125(16)30772-6

Cited by 13 publications

(2 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even more importantly, the drugs used most commonly for arrhythmia suppression, such as the class I agents, might not have equivalent efficacy and might even be more likely to cause proarrhythmia. Stud ies in large groups of such patients will be required to prove the efficacy of agents with novel electrophysiologic effects such as the class III drugs [37], A most common clinical syndrome is mi tral valve prolapse. Generally a benign con dition, mitral valve prolapse may be associ ated with sudden death in a very small mi nority of patients [38], However, ventricular arrhythmia is a common finding in patients with prolapse.…”

Section: Approach To Nonischemic Heart Diseasementioning

confidence: 99%

Clinical Management of Patients with Nonsustained Ventricular Tachycardia: What Do We Really Know?

et al. 1990

View full text Add to dashboard Cite

The management of patients with nonsustained ventricular tachycardia remains one of the most difficult tasks facing the practicing cardiologist. This common arrhythmia is a marker for death and morbid events in patients with a variety of forms of heart disease, but there is as yet no conclusive evidence that its suppression confers benefit. This paper will review the methods now available to risk stratify patients who have repetitive forms on electrocardiographic monitoring, their advantages and limitations. We will also review some of the trials which have attempted to prove that arrhythmia suppression improves survival. Finally, we will try to provide some recommendations to the clinician, based on what we know about this common arrhythmia. Though we will concentrate our attention on ischemic heart disease, we will briefly discuss the preferred management of patients with other forms of heart disease in whom the presence of nonsustained ventricular tachycardia has prognostic significance. We would like to emphasize that this is a rapidly changing field, and that treatment approaches will necessarily change, based on the results of ongoing clinical trials. The physician must not rigidly adhere to any treatment policy, but rather alter his or her approach based on the development of new information.

show abstract

Section: Approach To Nonischemic Heart Diseasementioning

confidence: 99%

Clinical Management of Patients with Nonsustained Ventricular Tachycardia: What Do We Really Know?

et al. 1990

View full text Add to dashboard Cite

show abstract

“…In our studies in healthy volunteers, it was noticed that some subjects experianced central nervous system (e~S) discomforts such as light -headedness and giddiness which lasted for several hours after intravenous (100 mg) or oral (300 mg) doses soon after administration (7,8). It is suggested that the anti -arrhythmic action of ethmozine may be in part a result of its phenothazine -like configuration and the neurophysiological effects of the drug may be of some significance in its anti -arrhythmic effects (9). In the present study, we have measured the concentrations of ethmozine in the cerebrospinal fluid (eSF) and plasma, in rabbit, after an intravenous …”

Section: Introductionmentioning

confidence: 99%

Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits

Chan

Yang

Wai

et al. 1989

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

The concentration-time profiles of ethmozine, a newly introduced anti-arrhythmic drug, in the cerebrospinal fluid (CSF) and plasma of six rabbits (New Zealand white rabbits of both sexes, 4.0-5.0 Kg) were studied after intravenous bolus administration. CSF samples at various intervals were obtained while the animal was lightly anaesthetized with intravenous thiopentone (40 mg Kg-1) and blood samples at other intervals were taken while the animal was conscious. Blood samples (1 ml) were collected from the implanted cannula of the ear artery while CSF samples (0.3 ml) were obtained from the cisterna magna. The plasma concentrations of ethmozine in six rabbits declined rapidly after intravenous injection for up to 30 min. then slowly over 12 h. Using non-compartmental analysis, the mean (+/- S.E.M.) elimination half-life, mean residence time, plasma clearance and volume of distribution at steady state were 13.9 +/- 9.2 h, 19.9 +/- 13.4 h, 2.3 Lh-1 and 26.8 +/- 7.9 L respectively. The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively. The results suggest that ethmozine is able to penetrate into the CSF from the general circulation and this may be related to its adverse effects on the central nervous system.

show abstract

Hemodynamic Monitoring, Pharmacologic Therapy, and Arrhythmia Management in Acute Congestive Heart Failure

Vincent¹

1994

Congestive Heart Failure

View full text Add to dashboard Cite

Newer Antiarrhythmic Drugs

Cited by 13 publications

References 223 publications

Clinical Management of Patients with Nonsustained Ventricular Tachycardia: What Do We Really Know?

Clinical Management of Patients with Nonsustained Ventricular Tachycardia: What Do We Really Know?

Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits

Hemodynamic Monitoring, Pharmacologic Therapy, and Arrhythmia Management in Acute Congestive Heart Failure

Contact Info

Product

Resources

About